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 factors, together with family dynamics and socioeconomic 
status, contribute to the poor long-term outcomes and de-
creased quality of life (QoL) for these patients and their fam-
ilies.  Key Messages: Care for the adolescent CKD/ESKD 
population is uniquely challenging, but research has identi-
fied ways in which we can continue to improve long-term 
outcomes and QoL for adolescents with CKD/ESKD. 
 © 2016 S. Karger AG, Basel 
 Introduction 
 Children, adolescents, and young adults constitute less 
than 5% of the end-stage kidney disease (ESKD) popula-
tion and their 10-year survival ranges from 70 to 85%  [1, 
2] . Despite these figures, their mortality rate is still 30 
times higher than their healthy peers  [1] . They mainly die 
of cardiovascular causes and infection rather than from 
renal failure  [3] . Adolescents with CKD and ESKD experi-
ence the physical and psychological demands of puberty 
while having to learn to self-manage their comorbidities. 
In this manuscript, we will discuss some of the unique 
characteristics of this patient population and give the pro-
viders suggestions for their care.
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 Abstract 
 Background: Adolescents and young adults face unique and 
complex physical, psychological, and family challenges. De-
spite improvements in care for chronic kidney disease (CKD) 
and end-stage kidney disease (ESKD), long-term mortality 
for children, adolescents, and young adults with CKD re-
mains substantially higher than their healthy counterparts. 
 Summary: In this article, we discuss the complex challenges 
that adolescent and young adult CKD/ESKD patients face. 
Adolescents have different CKD etiologies and progress 
along a course dissimilar to the adult population, but have 
similar multifarious comorbidities. In the setting of puberty 
and learning to become self-sufficient, adolescence is a crit-
ical time for growth and psychosocial development. Physi-
ological complications of CKD underlie many of the long-
term outcomes. CKD-mineral and bone disorder and anemia 
are particularly challenging given that they are exacerbated 
by the rapid growth of adolescents. Endocrine imbalances 
and malnutrition can delay and limit growth. All of these 
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 Causes of CKD 
 While congenital anomalies of the kidneys and urinary 
tract account for 73% of ESKD patients in the 0–1 years 
age group, this figure diminishes to 38.7% in the older 
than 12 years age group  [2] . Glomerulonephritis and focal 
segmental glomerulosclerosis account for one-third of di-
agnoses in the older than 12 years age group (16.5 and 
16.2%, respectively)  [2] .
 Growth and Sexual Development 
 CKD/ESKD affect growth due to multiple factors in-
cluding metabolic acidosis, decreased caloric intake, met-
abolic bone disease, reduced gonadal hormone produc-
tion, growth hormone resistance, and increased levels of 
IGF-1 binding proteins  [4] . These patients often present 
with a delay in puberty, but its onset may lead to a faster 
decline in renal function  [5] .
 CKD-Mineral and Bone Disorder 
 Adolescence is a crucial time for accrual of skeletal 
mass with approximately 25% of this mass being laid 
down during the 2-year period of peak height velocity  [6] . 
Both bone mass and bone strength are known to be af-
fected by the uremic state, and as such, adolescents with 
CKD experience changes in bone modeling/remodeling 
that may ultimately impact their quality of life (QoL) and 
long-term health. In addition, there has been increasing 
appreciation in the last decade of the cardiovascular cal-
cifications that are associated with CKD, along with the 
resultant increase in mortality related to cardiovascular 
disease for these patients  [7, 8] . As such, the triad of bone 
disease, disordered mineral metabolism, and cardiovas-
cular disease in the setting of renal dysfunction, is now 
referred to as ‘CKD-mineral and bone disorder’, or CKD-
MBD  [9] . CKD-MBD is the result of complex signaling 
mechanisms between the skeleton, kidneys, and parathy-
roid glands in the setting of renal dysfunction, which 
leads to alterations in serum values of calcium, phospho-
rus, FGF23 (a bone-derived regulator of phosphate me-
tabolism), parathyroid hormone (PTH) and vitamin D 
metabolites  [7, 8] . These changes have been shown to oc-
cur early in the course of CKD with evidence of increased 
levels of FGF23 in patients with stage 2 CKD  [7] .
 The clinical manifestations of CKD-MBD in the 
 adolescent population are a source of significant mor-
bidity and mortality, and include such entities as bone 
pain, myopathy, fractures and cardiovascular calcifica-
tions, in addition to poor growth in those with an ear-
lier onset of CKD  [6] . As such, it is imperative for pro-
viders caring for adolescents with CKD to be vigilant in 
monitoring biochemical parameters (calcium, phos-
phorus, PTH, and alkaline phosphatase) in order to 
minimize these complications. Bone biopsy remains the 
gold standard for assessing renal bone disease; however, 
it is not widely used in the care of adolescents with 
CKD. The Kidney Disease Outcomes Quality Initiatives 
(KDOQI) endorses a bone biopsy for the following clin-
ical indications: (1) pathological fractures, (2) unex-
plained hypercalcemia and (3) concern for aluminum 
toxicity  [10] . Dual X-ray absorptiometry is not recom-
mended for use in children with CKD due to its sub-
stantial limitations in this population, a position en-
dorsed by both the National Kidney Foundation 
 (KDOQI guidelines) and the International Society for 
Clinical Densitometry  [11] .
 The management of CKD-MBD involves maintain-
ing serum calcium and phosphorus within the normal 
range for age, treating 25 (OH) vitamin D deficiency if 
present, and maintaining a serum PTH level appropri-
ate for the level of CKD. In adolescents, calcium- 
containing phosphate binders remain the most widely 
used; however, it is recommended that the total daily 
intake of elemental calcium, from both the diet and 
phosphate binders, not surpass 2.5 g per day in order to 
minimize the risk for cardiovascular calcifications  [12] . 
Thus, a calcium-free phosphate binder may be useful in 
the adolescent with persistent hypercalcemia, as well as 
correcting metabolic acidosis in pediatric patients  [13, 
14] .
 The treatment of 25 (OH) vitamin D deficiency in 
children and adolescents with CKD delays the onset of 
secondary hyperparathyroidism  [13, 15] . Thus, guide-
lines endorse treatment of 25 (OH) vitamin D deficien-
cy/insufficiency in the setting of an elevated PTH with 
ergocalciferol/cholecalciferol first. In regard to active 
vitamin D analogs, a 2010 Cochrane review showed a 
similar decrease in PTH levels with all preparations 
studied  [13, 16] . However, oversuppression of PTH lev-
els with active vitamin D sterols is associated with a dy-
namic bone disease with resultant growth failure in 
younger children and teens  [13] . Currently, the calcimi-
metic agent, cinacalcet, is not approved for use in chil-
dren under the age of 18 years. However, pediatric ran-
domized controlled trials are underway, which may 
provide important data that would allow their use in the 





younger adolescent population, which would likely de-
crease the need for subtotal parathyroidectomy in this 
population.
 Anemia 
 Anemia is a frequent complication of CKD with in-
creasing prevalence as this condition progresses, thereby 
affecting nearly all patients on dialysis. The etiology of 
anemia in the adolescent population with CKD is often 
multifactorial. While in women menstruation alterations 
play an important role, erythropoietin deficiency remains 
the principal cause. Other important contributors in-
clude blood loss, iron deficiency, vitamin deficiency/poor 
nutrition, inflammation, poorly controlled hyperpara-
thyroidism, medications (e.g., angiotensin converting en-
zyme inhibitors and angiotensin receptor blockers), inad-
equate dialysis, and systemic disease  [17, 18] .
 The systemic effects of anemia in the adolescent age 
group are considerable, including fatigue, depression, 
sleep disturbance, impaired cognitive function, loss of ap-
petite and decreased exercise tolerance, ultimately result-
ing in poor QoL  [17] . In addition, anemia has a significant 
impact on overall health outcomes given its association 
with cardiovascular complications, such as left ventricu-
lar hypertrophy, blood transfusions resulting in human 
leukocyte antigen sensitization and potential decreased 
probability of renal transplantation, and increased mor-
tality  [18] .
 Given these substantial effects on the long-term 
health of the adolescents with CKD, as well as on their 
QoL, providers should monitor for the development of 
anemia and iron deficiency in this population. The 
threshold to diagnose anemia in children with CKD is 
age dependent, but approaches the KDOQI standard for 
adult females of <12 g/dl for children age of 12–15 years 
 [9] . Iron studies should be obtained in all adolescents 
with CKD, regardless of use of an erythropoietin stimu-
lating agent (ESA), with a goal transferrin saturation 
>20% and serum ferritin level >100 ng/ml, though the 
utility of the serum ferritin level as a measure of iron sta-
tus has been questioned based on recent studies, as it is 
thought to be more reflective of the inflammatory state 
 [13] . The preferred initial route of administration for 
iron is by mouth, except in those who are on mainte-
nance hemodialysis  [10] .
 The timing of ESA initiation should take into account 
benefits such as better QoL, improved school attendance 
and performance, and averting transfusions. It is recom-
mended that ESA initiation occur in pediatric patients 
with hemoglobin of 9–10 g/dl, with a target range of 11–
13 g/dl  [17] .
 Hypertension 
 Hypertension is the most common complication of 
CKD/ESKD as it affects up to 80% of children and ado-
lescents with this condition. It is thought to derive from 
volume expansion, excess renin or iatrogenic (corticoste-
roids, cyclosporine, tacrolimus) causes. Anemia, CKD-
MBD, chronic inflammation, oxidant stress, and dyslip-
idemia increase the risk for poor cardiovascular outcomes 
 [19] . Aggressive control of blood pressure (based on nor-
mal age ranges), lipid metabolism, and anemia is critical 
in these patients. Control of anemia and hypertension 
will improve neuro-cognition and school performance.
Other Comorbidities of CKD
 Endocrine dysfunction in adolescents with CKD/
ESKD often presents as ‘sick euthyroid syndrome’ (low 
total and free T4 and T3, but normal thyroid-stimulating 
hormone, and normal or decreased thyrotropin releasing 
hormone) and gonadal hormone abnormalities. Males 
and females both have increased luteinizing hormone 
and follicle stimulating hormone levels. Men have less tes-
tosterone and adrenal androgens while women have less 
estrogen and loss of luteinizing hormone pulsatile pat-
tern  [20] . There is little information regarding pregnancy.
 Difficulty with nutrition and nutrient utilization leads 
to uremic malnutrition. Uremia presents with a constella-
tion of signs and symptoms, characterized by anorexia, 
nausea, vomiting, growth retardation, peripheral neuropa-
thy, and CNS abnormalities (cognitive impairment, loss of 
concentration, lethargy, seizures, coma or death)  [21] . Ure-
mic patients also have a risk for bleeding secondary to ab-
normal platelet adhesion and aggregation properties  [20] .
 Psychosocial Aspects of CKD 
 Similar to other adolescents with a chronic health con-
dition, those with CKD/ESKD face challenges to their psy-
chosocial well-being including altered body image due to 
medication effects (i.e., steroids or cyclosporine) or proce-
dures (i.e., dialysis access), as well as absence from normal 
age-appropriate activities (i.e., school). Children and ado-
lescents with CKD have considerably lower health-related 
QoL compared to their healthy peers in four important 
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domains including physical, school, emotional, and social 
 [22] . Surprisingly, those patients who were older and had 
a longer duration of disease had higher scores in the phys-
ical, emotional, and social functioning domains  [22] . 
However, the older patients had lower scores in the school 
domain, which may be related to impaired neurocognitive 
function  [17] . Interestingly, in another study, dialysis pa-
tients scored equally, or higher, than their transplant 
counterparts in all QoL domains  [23] .
 In addition to altered QoL, adolescents with CKD/
ESKD are at higher risk for depression compared to their 
healthy peers. In a study by Kogon et al.  [24] , 30% of the 
study patients, age 9–18 years with CKD stages 3–5, met 
criteria for depression, compared to the reported rate of 
0.4–8.3% in the general child and adolescent population. 
Depression was more common in those over the age of 13 
(34%) compared to 18% in those under the age of 13 years 
 [24] . Given the prevalence of depression in the adolescent 
CKD/ESKD population, and its potential impact on oth-
er aspects of care (i.e., adherence), providers should be 
routinely screening patients for depressive symptoms.
 Once a diagnosis of depression is made, appropriate 
therapeutic interventions must be instituted. Data from 
the adult literature suggest that depression in patients 
with CKD/ESKD is undertreated and medications unde-
rutilized  [25] . This may be related to the exclusion of pa-
tients with CKD/ESKD from pharmacologic trials due to 
safety concerns. Until data from RCTs are available in this 
population, if a trial of medication is considered, selective 
serotonin reuptake inhibitors are the preferred medica-
tion class  [25] . In addition to pharmacologic treatment, 
another treatment option for depression, which has been 
studied in the adult CKD population, is cognitive behav-
ioral therapy. Data show that cognitive behavioral thera-
py is effective in reducing CKD patients’ scores on a wide-
ly-used depression screen  [26] .
 Family Aspects of Adolescent CKD 
 The burden of care for adolescents with CKD is sub-
stantial, and while adolescents are learning to take more 
responsibility for their care, parents and other caregivers 
are still primarily responsible for supervision and delivery 
of this care. One example includes the number of medica-
tions needed by adolescents with CKD. Using the Chron-
ic Kidney Disease in Children cohort, it was demonstrat-
ed that the number of medications needed for CKD-re-
lated comorbidities increased with CKD stage (2.5-fold 
for stage 4 vs. stage 2)  [27] . Interestingly, medication non-
adherence in this study population was associated with 
increased medication dosing frequency (more than 2 
times per day) rather than the number of medications. In 
addition to medication administration, caregivers assist 
with diet and fluid restrictions, blood pressure measure-
ments, injections (ESAs, growth hormone), and dialysis 
(peritoneal dialysis or home hemodialysis)  [17] .
 As such, it is not surprising that caregivers of youth 
with CKD have higher levels of psychological distress as 
well as decreased QoL  [28] . Lower socioeconomic status 
was also associated with reduced QoL for caretakers  [29] . 
Medway et al.  [28] recently explored the financial stress 
of caring for a child with CKD in an in-depth qualitative 
study. Parents in this study prioritized their child’s care, 
and as such, many were unable to maintain employment. 
In addition, many of these caregivers experienced diffi-
culty in accessing government support, which further 
contributed to financial stress. Many families were not 
aware of options available to alleviate ‘caregiver burnout’ 
and some of the financial burden, including respite care. 
Use of a multidisciplinary care team, including child life 
specialists and social workers, would be helpful for ad-
dressing these important needs of adolescent patients and 
their caregivers.
 Healthcare Transition, Self-Management and 
Adherence 
 Adolescents and young adults with CKD/ESKD must 
learn to manage their health in order to achieve good out-
comes and longer survival, particularly when their par-
 Fig. 1. Competing interests in adolescents with CKD/ESKD. Pa-
tients are represented as stars as we honor their resilience. 
Family/peersAdolescent with 
CKD/ESKD
Physical and mental health
School/work Dreams/goals
Financial issues





ents stop managing their condition. This can be achieved 
through a customized healthcare transition preparation 
at both the pediatric and adult-focused healthcare set-
tings, considering the patient/family’s culture and litera-
cy level. Healthcare transition readiness should be mea-
sured to monitor progress and make adjustments as 
needed, based on the level of cognition. For those with 
moderate to severe cognitive impairment, this prepara-
tion may only be focused on setting up a power of attor-
ney document and future living arrangements (i.e. group 
homes).
 There are a few published tools to measure transition 
readiness in patients with CKD/ESKD who speak English 
or Spanish  [30–33] . Early data show that patients who are 
women, older in age, Caucasians, or who have greater lit-
eracy skills or private insurance appear to have greater 
transition readiness  [31–33] , but further validation is un-
derway.
 Adherence in adolescents and young adults with CKD/
ESKD is an area of concern for all those involved (pa-
tients, parents, health providers). But, adherence has been 
an elusive concept to study as an agreed upon definition 
is yet to occur. Patients with a renal transplant have less 
room for error than those with CKD. Transplant patients 
should be encouraged to take their medications at a 95% 
rate or have immunosuppressive levels that range less 
than 2 standard deviations. Interventions such as text 
messaging or interactive patient education platforms are 
being tested in clinical trials.
Adherence to medical treatment may take second 
place in the adolescents’ minds as they have other com-
peting interests such the need to be like their peers, finan-
cial issues, school/work, goals and dreams ( fig. 1 ). In this 
figure, we represent the adolescent patient as a star, be-
cause in our opinion, these patients deserve our respect 
and understanding while honoring their resilience and 
ability to cope with such a devastating diagnosis. This re-
silience may explain their greater reported QoL com-
pared to what their parents report as proxy in several 
studies. 
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